Dermatitis

Bestqool Launches Innovative Red Light Therapy Devices for Eczema Relief

Retrieved on: 
Friday, April 5, 2024
Skin care, Fibroblast, Health, Certification, RLT, Psoriasis, Adenosine triphosphate, Cell, Serotonin, Patient, Photobiology, Tissue, Rosacea, Mitochondrion, Mental health, History, Red, Quality of life, Dermatitis, Itch, Keratinocyte, Acne, Skin, Pollution, Erythema, Cytokine, Irritation, ATP, Immune system, Recurrence, Fatigue, Swelling, FDA, Waste, Medical device

Bestqool's advanced red light therapy offers a non-invasive, natural solution for managing this pervasive skin issue.

Key Points: 
  • Bestqool's advanced red light therapy offers a non-invasive, natural solution for managing this pervasive skin issue.
  • Combining red light therapy with topical ointments can be a complementary approach for effective eczema treatment.
  • Bestqool's latest range of portable red light therapy devices are designed to be both convenient and effective for home use.
  • Adding red light therapy to daily care and prevention can repair both inside and outside by lowering eczema recurrence and improving the quality of life.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Buddle Set to Disrupt the Complacent Diaper Rash Category with a New Approach Aimed at Prevention — and It Works.

Retrieved on: 
Tuesday, March 19, 2024
Cosmetics, Retail, Consumer, Other Retail, Parenting, Children, Baby, Maternity, Foam, Cream, Pediatrics, Health, Friction, Dermatitis, Infant, Trial of the century, Dermatology, Ceramide, Skin, Irritant, Parent, Petroleum jelly

Most diaper rash products on the market have existed for decades, with no meaningful improvements and a primary focus on simply treating diaper rash — which led Goodsprout co-founders Joelle and Gaylord VanGuilder to ask, “Why are we still using the same stuff?

Key Points: 
  • Most diaper rash products on the market have existed for decades, with no meaningful improvements and a primary focus on simply treating diaper rash — which led Goodsprout co-founders Joelle and Gaylord VanGuilder to ask, “Why are we still using the same stuff?
  • And why is diaper rash still such a common problem?”
    “There is a far better understanding of baby’s skin and diaper rash today than there was 30 years ago, when a lot of the legacy products were developed,” Joelle VanGuilder said.
  • The most effective approach is a system of products working together to optimize the health of baby’s bottom — the science-based, clinically proven Buddle Diaper Rash System.
  • “We couldn’t be more exited to bring a fresh understanding and approach to treating diaper rash.”

Taro Pharmaceuticals U.S.A., Inc. Expands OTC Portfolio for Children with the Introduction of bébé Bottoms™ Diaper Rash Crème Spray

Retrieved on: 
Thursday, March 28, 2024
Convenience, Zinc oxide, Chamomile, Dermatitis, Amazon, Paraben, Paracetamol, TLC, OTC, Skin, Fever, Safety, Pain, Parent

HAWTHORNE, N.Y., March 28, 2024 /PRNewswire/ -- While traditional diaper rash creams are thick, sticky, and messy, Taro's new bébé Bottoms Diaper Rash Crème Spray allows for easy, one-handed application of a gentle spray formula that is touch-free with no rubbing needed. The light spray, which is formulated with 10% zinc oxide, organic chamomile and calendula, effortlessly covers the affected area, creating a protective barrier that helps soothe baby's diaper rash while allowing skin to breath and heal. It's gentle enough to use at each diaper change to help prevent future irritation.

Key Points: 
  • Made with TLC – Thin Layer Care™ Technology, New bébé Bottoms™ Diaper Rash Crème Spray Combines Zinc Oxide (10%) with Soothing Chamomile and Calendula in a Convenient, No-Touch Spray Application
    HAWTHORNE, N.Y., March 28, 2024 /PRNewswire/ -- While traditional diaper rash creams are thick, sticky, and messy, Taro's new bébé Bottoms Diaper Rash Crème Spray allows for easy, one-handed application of a gentle spray formula that is touch-free with no rubbing needed.
  • It's gentle enough to use at each diaper change to help prevent future irritation.
  • Though gentle, new bébé Bottoms is made with 10% zinc oxide, which is dermatologically tested in its efficacy for both preventing and treating diaper rash.
  • New bébé Bottoms Diaper Rash Crème Spray is available to purchase on Amazon and will expand to other major retailers in the coming months.

NEW RESEARCH FINDS ADULTS, CHILDREN AND TEENS WITH ECZEMA EXPERIENCE SIGNIFICANT MENTAL HEALTH SYMPTOMS

Retrieved on: 
Wednesday, March 27, 2024
Research, Depression, Atopic dermatitis, Mental, Caregiver, Patient, CQD, Mental health, Child, Anxiety, Dermatitis, Flare, Pleasure, NEA, Emotion, Nursing

NOVATO, Calif., March 27, 2024 /PRNewswire/ -- The National Eczema Association (NEA) today announced the first publication from its real-world research on eczema and its impacts on mental health. The results were published in the journal Dermatitis in March 2024.

Key Points: 
  • In a new study, the NEA research team aimed to evaluate patient-reported mental health symptoms, their correlation with eczema severity, and patient-perceived associations of eczema and its impacts on mental health.
  • The survey included questions about eczema symptoms, mental health symptoms, perceptions of the connection between eczema and mental health, and experiences accessing mental health services.
  • The study findings illustrated that adults, children and teens with eczema experience a significant mental health burden that increases with eczema severity:
    70% of respondents reported that either their own or their child's mental health was impacted by eczema during the past year.
  • Those with more severe eczema symptoms were more likely to have 10+ days of poor mental health than those with less severe eczema symptoms.

The National Eczema Association Approved for $250,000 Engagement Award from PCORI

Retrieved on: 
Monday, March 18, 2024
CER, Communication, Eugene Washington, Patient, Research, Quality of life, Nature, Dermatitis, MBS, Investment, MPH, Way, NEA, FDA, Nursing

NOVATO, Calif., March 18, 2024 /PRNewswire/ -- The National Eczema Association (NEA) has been approved for a $250,000 funding award through the Eugene Washington PCORI Engagement Award Program, an initiative of the Patient-Centered Outcomes Research Institute (PCORI). The award will support a project titled "Paving the Way towards Meaningful Partnerships: Fostering Regional PCOR to Enhance Eczema Outcomes." The award period spans two years, from February 1, 2024 through Jan 31, 2026.

Key Points: 
  • NOVATO, Calif., March 18, 2024 /PRNewswire/ -- The National Eczema Association (NEA) has been approved for a $250,000 funding award through the Eugene Washington PCORI Engagement Award Program, an initiative of the Patient-Centered Outcomes Research Institute (PCORI).
  • The award will support a project titled "Paving the Way towards Meaningful Partnerships: Fostering Regional PCOR to Enhance Eczema Outcomes."
  • The PCORI Engagement Award will be directed by co-project leads Wendy Smith Begolka, MBS, chief strategy officer at NEA and Jessica K. Johnson, MPH, director of community engagement at NEA.
  • For more information on the PCORI Engagement Award and NEA's funded project, visit here .

More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study

Retrieved on: 
Sunday, March 10, 2024
Diagnosis, Pigment, LLY, Weill Cornell Medicine, Atopic dermatitis, Health equity, Alaska Natives, Patient, Education, PDCA, Advocate, Diversity, Adherence, Immunology, Research, American Academy, Human, Weill Cornell Medical Center, Dermatitis, African, Skin, Safety, Lilly, Eli Lilly and Company, AAD, Health, IGA, Almirall, Pharmaceutical industry

In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief.

Key Points: 
  • In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief.
  • These late-breaking results from a Phase 3 study are being presented today at the American Academy of Dermatology (AAD) Annual Meeting.
  • "People with skin of color are disproportionately affected by atopic dermatitis, often experiencing more severe symptoms, a delay in diagnosis and a lengthier timeframe to find appropriate treatment.
  • "With these initial results, Lilly is taking a step toward investigating the needs of people with skin of color affected by atopic dermatitis."

Herbal medicinal product: Oenotherae oleumArray, C: ongoing call for scientific data

Retrieved on: 
Wednesday, April 3, 2024
Hypersensitivity, Temperature, Oenothera, Health, Headache, Rash, Dermatitis, Patient, Committee, Herbal medicine, Seed, Date, Allergy, Nausea, Mouth, Skin, Stomach, Exanthem, Medicine, Dietary supplement

Overview

Key Points: 
  • Overview
    This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of evening primrose oil.
  • The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing evening primrose oil.
  • Herbal medicines containing these evening primrose oil preparations are usually available in solid forms to be taken by mouth.
  • Evening primrose oil preparations may also be found in combination with other herbal substances in some herbal medicines.

Entreprenista Announces Winners of Its 2023 Top 100 Women Business Leaders Awards Presented by Chase Ink

Retrieved on: 
Tuesday, February 20, 2024
Social media, Woman, Dream, Food, Growth, Skin, Soap, Dermatitis, Dave Kerpen, Cosmetics

Leading Membership Community for Founders Amplifies Stories of Outstanding Entrepreneurs

Key Points: 
  • New York, New York--(Newsfile Corp. - February 20, 2024) - The Entreprenista League, a leading membership community for ambitious, entrepreneurial women, is excited to ​​announce the winners of its 2023 Entreprenista 100 Awards .
  • The Entreprenista Awards, presented by Chase® Ink® , honors the achievements of 100 women business leaders across Technology, Retail, Non-Profit, Beauty, Legal, Advertising, Food and Beverage, and more.
  • This year's Entreprenista 100 Awards received numerous submissions from impressive leaders of women-owned businesses across the U.S.
  • Winners were determined by the Entreprenista leadership team alongside an esteemed selection committee made up of successful founders and business experts from within The Entreprenista League community.